Every Form 4 that Amicus Therapeutics, Inc (FOLD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FOLD filings page.
AMICUS THERAPEUTICS, INC. director Craig A. Wheeler disposed of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. Each reported transaction reflects a disposition to the issuer tied to consummation of the merger.
Wheeler surrendered 84,631 shares of Common Stock at $14.50 per share and no Common Stock remained directly owned afterward. He also disposed of multiple fully vested stock option awards, each cancelled and converted into a cash right based on the $14.50 per share merger price minus the option’s exercise price, multiplied by the shares underlying each option grant.
The cancelled options covered various exercise prices, including $5.96, $8.55, $10.27, $10.71, $12.00, $12.62, $12.81, $8.60 and $6.71 per share, with expiration dates ranging from 2026 to 2035. Following these actions, Wheeler no longer held Common Stock or the reported options directly.
Amicus Therapeutics director Margaret G. McGlynn reported disposing of her equity positions in connection with the consummation of the acquisition of Amicus by BioMarin Pharmaceutical Inc. She surrendered 94,631 shares of Common Stock, including 31,000 shares and 63,631 restricted stock units that vested in full at closing.
Multiple fully vested stock options were also cancelled and converted into cash. For each option, she became entitled to a cash payment equal to $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. Following these transactions, her reported direct holdings of Common Stock and options are shown as zero.
AMICUS THERAPEUTICS director Burke W. Whitman reported a full disposition of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc.
He disposed of 118,598 shares of Common Stock at $14.50 per share, a figure that includes 98,184 common shares and 20,414 restricted stock units that vested in full when the merger closed. Following this transaction, he no longer holds Amicus common stock.
Multiple fully vested stock option awards, each giving the right to buy Amicus common stock at exercise prices between $5.96 and $12.81 per share, were also cancelled at closing. Each option was converted into a cash payment equal to the difference between $14.50 per share and its exercise price, multiplied by the number of shares subject to that option, leaving no remaining Amicus options outstanding for this director.
Amicus Therapeutics director Glenn Sblendorio disposed of his equity stake in connection with the company’s acquisition by BioMarin Pharmaceutical. He surrendered 142,564 shares of Common Stock at $14.50 per share and 20,414 restricted stock units that vested in full at the merger closing.
Multiple fully vested stock option grants covering shares of Common Stock were also cancelled. For each option, Mr. Sblendorio became entitled to a cash payment equal to the excess of $14.50 per share over the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows no remaining direct stock or option holdings.
AMICUS THERAPEUTICS, INC. director Eiry Roberts reported disposing of equity in connection with the consummation of the company’s acquisition by BioMarin Pharmaceutical Inc.
The filing shows a disposition of 76,275 shares of Common Stock at $14.50 per share, tied to the merger consideration. Footnotes state this amount included 55,861 shares of Common Stock and 20,414 restricted stock units, with the restricted stock units vesting in full at closing of the merger.
Multiple fully vested stock option grants were also disposed of to the issuer and converted into a cash right. These covered 74,872, 42,467, 30,474, 45,423 and 40,625 underlying shares at exercise prices ranging from $5.96 to $12.62 per share. For each option, the holder became entitled to a cash payment equal to the excess of $14.50 per share over the applicable exercise price, multiplied by the number of shares subject to that option. Following these transactions, the reporting person shows 0 shares and 0 options held in this filing.
Amicus Therapeutics director Lynn Dorsey Bleil reported disposing of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, she disposed of 113,941 shares of Common Stock at $14.50 per share and her holdings in this filing fell to zero.
The footnotes state that the disposition occurred upon consummation of the Merger and that each reported stock option was cancelled and converted into a cash payment based on $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. The filing indicates that each option was fully vested or vested in full in connection with the Merger.
Amicus Therapeutics director Michael Aaron Kelly disposed of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical. He surrendered 72,468 shares of Common Stock at $14.50 per share, including 52,054 shares of Common Stock and 20,414 restricted stock units that vested at closing.
On the same date, several fully vested stock option grants covering 74,872, 42,467, 30,474, 45,423 and 36,111 shares of Common Stock were cancelled and converted into cash. For each option, the cash payment equaled the difference between the $14.50 merger price and the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows no remaining holdings from these awards.
AMICUS THERAPEUTICS director Michael Raab disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 115,857 shares of Common Stock were cancelled at $14.50 per share, with the cash value paid as part of the merger consideration.
Footnotes state this amount included 95,443 Common shares and 20,414 restricted stock units that fully vested at closing. Multiple fully vested stock options were also cancelled and converted into cash based on the $14.50 per-share merger price minus each option’s exercise price. After these transactions, Raab reported zero remaining direct holdings or outstanding options.
Amicus Therapeutics Chief Accounting Officer Samantha Prout reported the cash-out of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical. She disposed of 125,951 shares of Common Stock at $14.50 per share, a figure that includes 47,394 shares of Common Stock and 78,557 restricted stock units that vested in full when the merger was consummated.
Several grants of fully vested stock options covering Amicus Common Stock were also cancelled at closing and converted into cash. For each option grant, she became entitled to a cash payment equal to the difference between the $14.50 merger price and the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows she no longer holds Amicus common shares or stock options.
AMICUS THERAPEUTICS, INC. Chief Development Officer Jeff Castelli reported disposing of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, he disposed of 427,089 shares of Common Stock at $14.50 per share, including 318,417 shares of Common Stock and 108,672 restricted stock units that vested in full at closing.
Several fully vested stock option awards were also cancelled and converted into the right to receive cash equal to $14.50 per share minus each option’s exercise price, multiplied by the option share count. Following these dispositions, the filing shows no remaining Common Stock or stock options held directly by Castelli.
Amicus Therapeutics’ Chief People Officer David Michael Clark disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 221,811 shares of Common Stock were surrendered at $14.50 per share, including 130,942 shares and 90,869 restricted stock units that vested at closing.
Multiple fully vested stock option grants covering tens of thousands of shares each were cancelled and converted into cash. For each option, Clark became entitled to a cash payment equal to the excess of $14.50 over the option’s exercise price, multiplied by the shares subject to that option. Following these transactions, the Form 4 reports zero remaining direct holdings.
AMICUS THERAPEUTICS, INC. Chief Legal Officer Ellen Rosenberg reported disposing of her equity position in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. at $14.50 per share. The filing shows 463,898 directly held shares of common stock and related equity awards being cashed out as part of the merger terms.
An additional 15,000 shares of common stock held indirectly by her spouse were also disposed of at $14.50 per share. Several batches of stock options were cancelled and converted into cash based on the spread between the $14.50 merger price and their respective exercise prices, leaving no reported remaining options or common shares after the transaction.
Amicus Therapeutics Chief Financial Officer Simon N.R. Harford disposed of his equity in the company in connection with the consummation of its acquisition by BioMarin Pharmaceutical Inc.
The filing shows 143,595 shares of common stock were returned to the issuer at $14.50 per share, leaving Harford with zero directly held common shares. Footnotes explain that this disposition included 108,478 shares of common stock and 35,117 restricted stock units that vested in full when the merger closed.
Several stock option awards were also cancelled and converted into cash rights. Each option was exchanged for a cash payment equal to the difference between the $14.50 merger price and its exercise price, multiplied by the number of underlying shares. All reported options vested in full and, after these transactions, no stock options remain outstanding for Harford in this filing.
Amicus Therapeutics President and CEO Bradley L. Campbell reported the disposition of his equity interests in connection with the acquisition of Amicus by BioMarin Pharmaceutical. The filing shows 1,008,680 shares of Common Stock were disposed of, consisting of 689,467 shares and 319,213 restricted stock units that vested in full at closing of the merger.
The Form 4 also reports multiple stock option awards being disposed of to the issuer. Each option was cancelled at the merger closing and converted into a cash right equal to the excess of the $14.50 per share merger price over its exercise price, multiplied by the number of option shares. Following these transactions, the reported common shares and these options show zero remaining direct holdings.
Amicus Therapeutics President and CEO Bradley L. Campbell sold 22,500 shares of common stock in an open-market transaction. The sale took place at a weighted average price of $14.3484 per share on March 2, 2026, with individual trade prices ranging from $14.34 to $14.37. After this transaction, he continues to hold 998,680 shares of Amicus Therapeutics common stock directly.
Amicus Therapeutics President and CEO Bradley L. Campbell reported an option exercise and share sale. On January 20, 2026, he exercised 75,000 stock options with an exercise price of $6.10 per share, receiving 75,000 shares of common stock. That same day, he sold 75,000 shares of common stock at a weighted average price of $14.3091 per share, with individual sale prices ranging from $14.30 to $14.32.
Following these transactions, Campbell directly owned 1,021,180 shares of Amicus Therapeutics common stock. All options exercised were fully vested and exercisable as of the transaction date. The filing notes that all transactions were carried out under a Rule 10b5-1 trading plan adopted on September 12, 2025.
Amicus Therapeutics Chief Development Officer Jeff Castelli filed a Form 4 reporting two non-derivative transactions in the company’s common stock. On January 2, 2026, a transaction coded “F” involved the disposition of 6,905 shares at $14.27 per share, leaving 432,413 shares beneficially owned directly.
On January 3, 2026, a second “F” coded transaction reported the disposition of 23,102 shares at $14.27 per share, resulting in 409,311 shares of common stock beneficially owned directly after the transaction.
Amicus Therapeutics' president and CEO, who also serves as a director, reported option exercises and share sales in the company’s stock. On December 15, 2025, the insider exercised 70,426 stock options at an exercise price of $9.03 per share, acquiring the same number of common shares. On the same date, the insider sold 77,926 shares of common stock at a weighted average price of $10.8566 per share, with individual sale prices ranging from $10.60 to $11.11.
After these transactions, the insider directly beneficially owned 1,129,782 shares of Amicus Therapeutics common stock and held no remaining derivative securities from this option grant. All of the options exercised were already fully vested and exercisable, and all reported trades were carried out under a Rule 10b5-1 trading plan adopted on September 13, 2024.
Amicus Therapeutics, Inc. reported an insider stock transaction by its Chief People Officer. On 12/15/2025, the officer sold 25,643 shares of common stock at $11 per share. After this sale, the officer beneficially owned 271,332 shares of Amicus Therapeutics common stock.
All of the reported transactions were carried out under a pre-established Rule 10b5-1 trading plan that the reporting person adopted on March 14, 2025, indicating the sales were made according to a predetermined schedule rather than discretionary market timing.
Amicus Therapeutics (FOLD) reported an insider transaction by its Chief People Officer. On 11/04/2025, the officer sold 25,643 shares of common stock at a $9.5098 weighted-average price (range $9.50–$9.54).
Following the sale, the officer beneficially owns 322,618 shares, held directly. The transactions were effected under a Rule 10b5-1 trading plan adopted on March 14, 2025.